Wang Guo-jie, Xu Ji-ying, Wang Guo-bin, Zhen Xin-an, Gao San-you, Du Chang-mei
Tuberculosis Control Institute, Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450003, China.
Zhonghua Jie He He Hu Xi Za Zhi. 2006 Aug;29(8):527-30.
To study the impact of anti-tuberculosis drug resistance on treatment outcome of pulmonary tuberculosis (TB) patients receiving directly observed treatment strategy (DOTS) in Henan Province, China.
From Aug. 2001 to Jun. 2002, the second round surveillance of anti-TB drug resistance was carried out in cooperation with WHO in Henan Province, China. The proportion method was used for drug susceptibility test and all enrolled patients were administrated with DOTS.
The treatment success rate of smear-positive patients was 85.5% (1,343/1,571), of which the treatment success rate of initial-treatment cases was 89.6% (1,159/1,293). The treatment success rates among 565 anti-TB drug resistant cases and 215 multi-drug-resistant-TB (MDR-TB) cases were 76.6% (433/565), (initial treatment cases: 86.8%, 341/393; re-treated cases: 53.5%, 92/172; being significantly different), 58.6% (126/215), (initial treatment cases: 75.4%, 83/110; re-treated cases: 41.0%, 43/105; being significantly different), respectively. For the cases being resistant to 2, 3 or 4 drugs, the treatment success rates in initial treatment cases were all higher than those in re-treatment cases. Multivariate analysis showed that re-treatment, resistance to 2 plus drugs or MDR were the significant risk factors for treatment failure, and that re-treatment, older age and MDR were the significant risk factors for TB death.
The treatment outcome of initial treatment of smear-positive patients with DOTS in Henan was satisfying, but that of retreated patients, especially retreated patients of MDR was very poor. Re-treatment, older age, resistance to 2 anti-TB drugs or MDR were the risk factors for the poor outcome of treatment with DOTS.
研究耐多药结核病对在中国河南省接受直接督导下的短程化疗策略(DOTS)的肺结核患者治疗转归的影响。
2001年8月至2002年6月,在中国河南省与世界卫生组织合作开展第二轮抗结核药物耐药性监测。采用比例法进行药物敏感性试验,所有入选患者均接受DOTS治疗。
涂片阳性患者的治疗成功率为85.5%(1343/1571),其中初治病例的治疗成功率为89.6%(1159/1293)。565例耐多药结核病患者和215例耐多药结核病(MDR-TB)患者的治疗成功率分别为76.6%(433/565)(初治病例:86.8%,341/393;复治病例:53.5%,92/172;差异有统计学意义)、58.6%(126/215)(初治病例:75.4%,83/110;复治病例:41.0%,43/105;差异有统计学意义)。对于耐2种、3种或4种药物的病例,初治病例的治疗成功率均高于复治病例。多因素分析显示,复治、耐2种及以上药物或耐多药是治疗失败的重要危险因素,而复治、年龄较大和耐多药是结核病死亡的重要危险因素。
河南省采用DOTS策略对涂片阳性初治患者的治疗效果令人满意,但复治患者,尤其是耐多药复治患者的治疗效果很差。复治、年龄较大、耐2种抗结核药物或耐多药是DOTS治疗效果不佳的危险因素。